Vasoplegic syndrome: An update on perioperative considerations

Journal of Clinical Anesthesia

Volumn 40, Issue , 2017, Pages 63-71

  Liu, Henry ^a   Yu, Ling ^b   Yang, Longqiu ^c   Green, Michael S ^a  

^a HAHNEMANN UNIVERSITY HOSPITAL   (United States)

^b Hubei Women and Children's Hospital   (China)

^c Division of Medical Oncology   (China)

Author keywords

ACE inhibitor; Angiotensin receptor antagonist; ATP dependent K channels; Copeptin; Methylene blue; Nitric oxide; Nuclear factor B (NF B); V1A receptor; Vasoplegia; Vasoplegic syndrome

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ADRENERGIC RECEPTOR STIMULATING AGENT; AMIODARONE; ANGIOTENSIN II ANTAGONIST; APROTININ; CATECHOLAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; HYDROXOCOBALAMIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDIGO CARMINE; INDUCIBLE NITRIC OXIDE SYNTHASE; METHYLENE BLUE; POTASSIUM CHANNEL BLOCKING AGENT; PROTAMINE; PROTEIN INHIBITOR; SMALL INTERFERING RNA; VASOPRESSIN; VASOPRESSIN V1A RECEPTOR;

ANESTHESIOLOGIST; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; DOWN REGULATION; HUMAN; HYPERBARIC OXYGEN THERAPY; INJURY; MORBIDITY; MORTALITY; NONHUMAN; ORGAN TRANSPLANTATION; PATHOGENESIS; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEPSIS; VASOPLEGIA; BLOOD TRANSFUSION REACTION; COMPLICATION; POSTOPERATIVE COMPLICATION;

CARDIOPULMONARY BYPASS; HUMANS; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; TRANSFUSION REACTION; VASOPLEGIA; WOUNDS AND INJURIES;

EID: 85018883195     PISSN: 09528180     EISSN: 18734529     Source Type: Journal    
DOI: 10.1016/j.jclinane.2017.04.017     Document Type: Review

References (88)

1. [1] Laborit, H., Progressive vasoplegia during transfusion in post-shock vasomotor disequilibrium. Presse Med, 60(32), 1952 May 10, 692.
2. [2] Fischer, G.W., Levin, M.A., Vasoplegia during cardiac surgery: current concepts and management. Semin Thorac Cardiovasc Surg 22:2 (2010 Summer), 140–144 PMID: 21092891.
3. [3] Omar, S., Zedan, A., Nugent, K., Cardiac vasoplegia syndrome: pathophysiology, risk factors and treatment. Am J Med Sci 349:1 (2015 Jan), 80–88.
4. [4] Evora, P.R., Alves Junior, L., Ferreira, C.A., Menardi, A.C., Bassetto, S., Rodrigues, A.J., et al. Twenty years of vasoplegic syndrome treatment in heart surgery. Methylene blue revised. Rev Bras Cir Cardiovasc 30:1 (2015 Jan-Mar), 84–92 PMID: 25859872.
5. [5] Escarras, A., Aubert, L., Randria, H., Three cases of splanchnic vasoplegia (Reilly syndrome) after cranial traumatism. Mars Med 102:6 (1965), 574–577.
6. [6] Carrel, T., Englberger, L., Mohacsi, P., Neidhart, P., Schmidli, J., Low systemic vascular resistance after cardiopulmonary bypass: incidence, etiology, and clinical importance. J Card Surg 15:5 (2000 Sep-Oct), 347–353.
7. [7] Shanmugam, G., Vasoplegic syndrome—the role of methylene blue. Eur J Cardiothorac Surg 28 (2005), 705–710.
8. [8] Shear, T., Greenberg, S., Vasoplegic syndrome and rennin-angiotensin system antagonists. APSF Newsl 27:1 (2012), 18–19.
9. [9] Iribarren, J., Jimenez, J., Brouard, M., Lorenzo, J., Perez, R., Lorente, L., et al. Vasoplegic syndrome after cardiopulmonary bypass surgery – associated factors and clinical outcomes: a nested case-control study. Crit. Care, 11(Suppl. 2), 2007, P254, 10.1186/cc5414.
10. [10] Sun, X., Zhang, L., Hill, P.C., Lowery, R., Lee, A.T., Molyneaux, R.E., et al. Is incidence of postoperative vasoplegic syndrome different between off-pump and on pump coronary artery bypass grafting surgery?. Eur J Cardiothorac Surg 34:4 (2008 Oct), 820–825.
11. [11] Levin, R.L., Degrange, M.A., Bruno, G.F., Del Mazo, C.D., Taborda, D.J., Griotti, J.J., et al. Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Ann Thorac Surg 77:2 (2004 Feb), 496–499.
12. [12] Byrne, J.G., Leacche, M., Paul, S., Mihaljevic, T., Rawn, J.D., Shernan, S.K., et al. Risk factors and outcomes for ‘vasoplegia syndrome’ following cardiac transplantation. Eur J Cardiothorac Surg 25:3 (2004 Mar), 327–332.
13. [13] Alfirevic, A., Xu, M., Johnston, D., Figueroa, P., Koch, C.G., Transfusion increases the risk for vasoplegia after cardiac operations. Ann Thorac Surg 92:3 (2011 Sep), 812–819.
14. [14] Levin, M.A., Lin, H.M., Castillo, J.G., Adams, D.H., Reich, D.L., Fischer, G.W., Early on cardiopulmonary bypass hypotension and other factors associated with vasoplegic syndrome. Circulation 120:17 (2009 Oct 27), 1664–1671.
15. [15] Del Duca, D., Sheth, S.S., Clarke, A.E., Lachapelle, K.J., Ergina, P.L., Use of methylene blue for catecholamine-refractory vasoplegia from protamine and aprotinin. Ann Thorac Surg 87:2 (2009 Feb), 640–642.
16. [16] Gomes, W.J., Evora, P.R., Vasoplegic syndrome after off-pump coronary artery bypass surgery: a rising threat. Eur J Cardiothorac Surg 35:6 (2009 Jun), 1116–1117.
17. [17] Hossne Junior, N.A., Miranda, M., Monteiro, M.R., Branco, J.N., Vargas, G.F., Pestana, J.O., et al. Cardiopulmonary bypass increases the risk of vasoplegic syndrome after coronary artery bypass grafting in patients with dialysis-dependent chronic renal failure. Rev Bras Cir Cardiovasc 30:4 (2015 Jul–Aug), 482–488, 10.5935/1678-9741.20140092 PMID: 27163423.
18. [18] Xu, J., Long, C., Qi, R., Xie, L., Shi, S., Zhang, Y., Study of mechanism of vasoplegic syndrome for open heart surgery. Zhonghua Yi Xue Za Zhi 82:2 (2002 Jan 25), 127–130.
19. [19] Fischer, G.W., Bengtsson, Y., Scarola, S., Cohen, E., Methylene blue for vasopressor-resistant vasoplegia syndrome during liver transplantation. J Cardiothorac Vasc Anesth 24:3 (2010 Jun), 463–466.
20. [20] Denny, J.T., Burr, A.T., Balzer, F., Tse, J.T., Denny, J.E., Chyu, D., Methylene blue treatment for cytokine release syndrome-associated vasoplegia following a renal transplant with rATG infusion: a case report and literature review. Exp Ther Med 9:5 (2015 May), 1915–1920 PMID: 26136914.
21. [21] Hershman, E., Hadash, A., Attias, O., Ben-Ari, J., Methylene blue treatment for resistant shock following renal transplantation. Paediatr Anaesth 25:11 (2015 Nov), 1168–1169, 10.1111/pan.12742 PMID: 26428738.
22. [22] Patarroyo, M., Simbaqueba, C., Shrestha, K., Starling, R.C., Smedira, N., Tang, W.H., et al. Pre-operative risk factors and clinical outcomes associated with vasoplegia in recipients of orthotopic heart transplantation in the contemporary era. J Heart Lung Transplant 31:3 (2012 Mar), 282–287, 10.1016/j.healun.2011.10.010 PMID: 22112993.
23. [23] Carley, M., Schaff, J., Lai, T., Poppers, J., Methylene blue for vasoplegia when on cardiopulmonary bypass during double-lung transplantation. A A Case Rep. 5:8 (2015 Oct 15), 127–130, 10.1213/XAA.0000000000000190 PMID: 26466303.
24. [24] Jaskille, A.D., Jeng, J.C., Jordan, M.H., Methylene blue in the treatment of vasoplegia following severe burns. J Burn Care Res 29:2 (2008 Mar-Apr), 408–410.
25. [25] Church, J.T., Posluszny, J.A., Hemmila, M., To KB, Cherry-Bukowiec, J.R., Waljee, J., Methylene blue for burn-induced vasoplegia: case report and review of literature. J Burn Care Res 36:2 (2015 Mar–Apr), e107–e111 PMID: 25687361.
26. [26] de Souza, P., Schulz, R., da Silva-Santos, J.E., Matrix metalloproteinase inhibitors prevent sepsis induced refractoriness to vasoconstrictors in the cecal ligation and puncture model in rats. Eur J Pharmacol 765 (2015 Oct 15), 164–170, 10.1016/j.ejphar.2015.08.030 PMID: 26297976.
27. [27] Schmidt, C., Höcherl, K., Kurt, B., et al. Role of nuclear factor-[kappa]B-dependent induction of cytokines in the regulation of vasopressin V1A-receptors during cecal ligation and puncture induced circulatory failure. Crit Care Med 36 (2008), 2363–2372.
28. [28] Ramamoorthy, S., Patel, S., Bradburn, E., Kadry, Z., Uemura, T.K., Janicki, P., et al. Bezinover D use of methylene blue for treatment of severe sepsis in an immunosuppressed patient after liver transplantation. Case Rep Transplant, 2013, 2013, 203791 PMID: 23762740.
29. [29] Zheng, W., Kou, Y., Gao, F.L., Ouyang, X.H., Enzymatic changes in myosin regulatory proteins may explain vasoplegia in terminally ill patients with sepsis. Biosci Rep, 36(2), 2016 Jan 15 pii: e00305 10.1042/BSR20150207 PMID: 26772992.
30. [30] Moreno, G.E., Charroqui, A., Pilán, M.L., Magliola, R.H., Krynski, M.P., Althabe, M., et al. Clinical experience with berlin heart Excor in pediatric patients in Argentina: 1373 days of cardiac support. Pediatr Cardiol 32:5 (2011 Jun), 652–658, 10.1007/s00246-011-9949-0.
31. [31] Garatti, A., Colombo, T., Russo, C., Lanfranconi, M., Bruschi, G., Milazzo, F., et al. Impella recover 100 microaxial left ventricular assist device: the Niguarda experience. Transplant Proc 36:3 (2004 Apr), 623–626.
32. [32] Raja, S.G., Dreyfus, G.D., Vasoplegic syndrome after off-pump coronary artery bypass surgery: an unusual complication. Tex Heart Inst J 31:4 (2004), 421–424.
33. [33] Raja, S.G., Fida, N., Should angiotensin converting enzyme inhibitors/angiotensin II receptor antagonists be omitted before cardiac surgery to avoid postoperative vasodilation?. Interact Cardiovasc Thorac Surg 7:3 (2008 May), 470–475.
34. [34] Smith, I., Jackson, I., Beta-blockers, calcium channel blockers, angiotensin converting enzyme inhibitors and angiotensin receptor blockers: should they be stopped or not before ambulatory anaesthesia?. Curr Opin Anaesthesiol 23:6 (2010 Dec), 687–690 PMID: 20805745.
35. [35] Ozal, E., Kuralay, E., Yildirim, V., Kilic, S., Bolcal, C., Kücükarslan, N., et al. Preoperative methylene blue administration in patients at high risk for vasoplegic syndrome during cardiac surgery. Ann Thorac Surg 79:5 (2005 May), 1615–1619.
36. [36] Bertrand, M., Godet, G., Meersschaert, K., Brun, L., Salcedo, E., Coriat, P., Should the angiotensin II antagonists be discontinued before surgery?. Anesth Analg 92 (2001), 26–30.
37. [37] Roshanov, P.S., Rochwerg, B., Patel, A., et al. Withholding versus continuing angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers before noncardiac surgery: an analysis of the vascular events in noncardiac surgery patients cohort evaluation prospective cohort. Anesthesiology 126:1 (2017 Jan), 16–27, 10.1097/ALN.0000000000001404 PMID: 27775997.
38. [38] Van Dyck, M., Baele, P., Rennotte, M.T., Matta, A., Dion, R., Kestens-Servaye, Y., Should amiodarone be discontinued before cardiac surgery?. Acta Anaesthesiol Belg 39:1 (1988), 3–10 PMID: 3285632.
39. [39] Shieh, J.P., Chu, C.C., Chen, J.Y., Chen, Y.H., Yeh, F.C., Hsing, C.H., Acute fatal vasoplegia and asystole induced by intravenous amiodarone after cardiopulmonary bypass in a patient with preoperative cardiogenic shock. Acta Anaesthesiol Sin 37:4 (1999 Dec), 205–210 PMID:10670119.
40. [40] Mekontso-Dessap, A., Houël, R., Soustelle, C., Kirsch, M., Thébert, D., Loisance, D.Y., Risk factors for post-cardiopulmonary bypass vasoplegia in patients with preserved left ventricular function. Ann Thorac Surg 71:5 (2001 May), 1428–1432 PMID: 11383777.
41. [41] Graham, R.E., Cartner, M., Winearls, J., A severe case of vasoplegic shock following metformin overdose successfully treated with methylene blue as a last line therapy. BMJ Case Rep, 2015, 2015 Jul 6 pii: bcr2015210229 10.1136/bcr-2015-210229 PMID: 26150642.
42. [42] Bernard, C., Szekely, B., Philip, I., Wollman, E., Payen, D., Tedgui, A., Activated macrophages depress the contractility of rabbit carotids via an L-arginine/nitric oxide-dependent effector mechanism. Connection with amplified cytokine release. J Clin Invest 89:3 (1992 Mar), 851–860.
43. [43] McKenna, T.M., Clegg, J.M., Williams, T.J., Protein kinase C is a mediator of lipopolysaccharide induced vascular suppression in the rat aorta. Shock 2:2 (1994 Aug), 84–89.
44. [44] Speziale, G., Ruvolo, G., Marino, B., A role for nitric oxide in the vasoplegic syndrome. J Cardiovasc Surg (Torino) 37:3 (1996 Jun), 301–303.
45. [45] Jochberger, S., Velik-Salchner, C., Mayr, V.D., et al. The vasopressin and copeptin response in patients with vasodilatory shock after cardiac surgery: a prospective, controlled study. Intensive Care Med 35:3 (2009 Mar), 489–497 PMID: 18825368.
46. [46] Landry, D.W., Oliver, J.A., The ATP-sensitive K-channel mediates hypotension in endotoxemia and hypoxic lactic acidosis in dog. J Clin Invest 89 (1992), 2071–2074.
47. [47] Landry, D.W., Levin, H.R., Gallant, E.M., et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 95 (1997), 1122–1125.
48. [48] Brackett, D.J., Schaefer, C.F., Wilson, M.F., The role of vasopressin in the maintenance of cardiovascular function during early endotoxin shock. Adv Shock Res 9 (1983), 147–156.
49. [49] Reid, I.A., Role of vasopressin deficiency in the vasodilation of septic shock. Circulation 95 (1997), 1108–1110.
50. [50] Wagener, G., Kovalevskaya, G., Minhaz, M., Mattis, F., Emond, J.C., Landry, D.W., Vasopressin deficiency and vasodilatory state in end-stage liver disease. J Cardiothorac Vasc Anesth 25:4 (2011 Aug), 665–670, 10.1053/j.jvca.2010.09.018 PMID: 21126886.
51. [51] Landry, D.W., Oliver, J.A., The pathogenesis of vasodilatory shock. N Engl J Med 345 (2001), 588–595.
52. [52] Warrillow, S., Egi, M., Bellomo, R., Randomized, double-blind, placebo-controlled crossover pilot study of a potassium channel blocker in patients with septic shock. Crit Care Med 34:4 (2006 Apr), 980–985 PMID: 16484892.
53. [53] Salzman, A.L., Vromen, A., Denenberg, A., et al. KATP-channel inhibition improves hemodynamics and cellular energetics in hemorrhagic hemorrhagic shock. Am J Physiol 272 (1997), H688–H694.
54. [54] Zhao, K.S., Xuliang, J.L., Huang, Q., et al. New approach to treatment of shock: restitution of vasoreactivity. Shock 18 (2002), 189–192.
55. [55] Geisen, K., Am, Vegh, Krause, E., et al. Cardiovascular effects of conventional sulfonylureas and glimepiride. Horm Metab Res 28 (1996), 496–50732.
56. [56] Gribble, F.M., Ashcroft, F.M., Sulfonylurea sensitivity of adenosine triphosphate-sensitive potassium channels from beta cells and extrapancreatic tissues. Metabolism 49:10 Suppl 2 (2000), 3–6.
57. [57] Kerbaul, F., Bénard, F., Giorgi, R., Youlet, B., Carrega, L., Zouher, I., et al. Adenosine A2A receptor hyperexpression in patients with severe SIRS after cardiopulmonary bypass. J Invest Med 56:6 (2008 Aug), 864–871, 10.2310/JIM.0b013e3181788d02 PMID: 18667904.
58. [58] Kerbaul, F., Collart, F., Giorgi, R., et al. Role of endogenous adenosine as a predictive marker of Vasoplegia during cardiopulmonary bypass and postoperative severe systemic inflammatory response. Crit Care Med 34:3 (2006 Mar), 640–645.
59. [59] Russell, J.A., Walley, K.R., Singer, J., et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 358 (2008), 877–887.
60. [60] Knuefermann, P., Boehm, O., Baumgarten, G., Zacharowski, K., Sepsis-induced vasoplegia–is vasopressin V1A-receptor a new target?. Crit Care Med 36:8 (2008 Aug), 2468–2469.
61. [61] Liu, M., Zhang, Y., Xiong, J.Y., Wang, Y., Lv, S., Etomidate mitigates lipopolysaccharide-induced CD14 and TREM-1 expression, NF-κB activation, and pro-inflammatory cytokine production in rat macrophages. Inflammation, 17, 2015 Sep PMID: 26383906.
62. [62] Gomes, W.J., Carvalho, A.C., Palma, J.H., Teles, C.A., Branco, J.N., Silas, M.G., et al. Vasoplegic syndrome after open heart surgery. J Cardiovasc Surg (Torino) 39:5 (1998 Oct), 619–623.
63. [63] Gomes, W.J., Carvalho, A.C., Palma, J.H., Gonçalves, I. Jr., Buffolo, E., Vasoplegic syndrome: a new dilemma. J Thorac Cardiovasc Surg 107:3 (1994 Mar), 942–943.
64. [64] Jeong, S.M., Postreperfusion syndrome during liver transplantation. Korean J Anesthesiol 68:6 (2015 Dec), 527–539 PMID: 26634075.
65. [65] de Armas, L.C., Castillo, Y.A., Is it possible to distinguish between vasoplegic syndrome and postreperfusion syndrome during liver graft reperfusion?. Anesth Analg 110:3 (2010 Mar 1), 969–970 PMID: 20185672.
66. [66] Colson, P.H., Bernard, C., Struck, J., Morgenthaler, N.G., Albat, B., Guillon, G., Post cardiac surgery vasoplegia is associated with high preoperative copeptin plasma concentration. Crit Care, 15(5), 2011, R255.
67. [67] Bezinover, D., McQuillan, P., Rossignol, J., Uemura, T., Kadry, Z., Janicki, P., Vasoplegic shock during liver transplantation: is the preoperative cGMP plasma level a potential predictor of hemodynamic instability?. Med Sci Monit 16:9 (2010 Sep), CS114–CS117 PMID: 20802421.
68. [68] Masetti, P., Murphy, S.F., Kouchoukos, N.T., Vasopressin therapy for vasoplegic syndrome following cardiopulmonary bypass. J Card Surg 17:6 (2002 Nov–Dec), 485–489.
69. [69] Papadopoulos, G., Sintou, E., Siminelakis, S., Koletsis, E., Baikoussis, N.G., Apostolakis, E., Perioperative infusion of low- dose of vasopressin for prevention and management of vasodilatory vasoplegic syndrome in patients undergoing coronary artery bypass grafting-a double-blind randomized study. J Cardiothorac Surg, 5, 2010 Mar 28, 17 PMID: 20346182.
70. [70] Hajjar, L.A., Vincent, J.L., Barbosa Gomes Galas, F.R., et al. Vasopressin versus norepinephrine in patients with Vasoplegic shock after cardiac surgery: the VANCS randomized controlled trial. Anesthesiology 126:1 (2017 Jan), 85–93, 10.1097/ALN.0000000000001434 PMID: 27841822.
71. [71] Noto, A., Lentini, S., Versaci, A., Giardina, M., Risitano, D.C., Messina, R., et al. A retrospective analysis of terlipressin in bolus for the management of refractory vasoplegic hypotension after cardiac surgery. Interact Cardiovasc Thorac Surg 9:4 (2009 Oct), 588–592 PMID: 19581293.
72. [72] Leyh, R.G., Kofidis, T., Struber, M., et al. Methylene blue: the drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass?. J Thorac Cardiovasc Surg 125 (2003), 1426–1431.
73. [73] Dagenais, F., Mathieu, P., Rescue therapy with methylene blue in systemic inflammatory response syndrome after cardiac surgery. Can J Cardiol 19:2 (2003 Feb), 167–169.
74. [74] Kofidis, T., Strüber, M., Wilhelmi, M., Anssar, M., Simon, A., Harringer, W., et al. Reversal of severe vasoplegia with single-dose methylene blue after heart transplantation. J Thorac Cardiovasc Surg 122:4 (2001 Oct), 823–824.
75. [75] Evora, P.R., Levin, R.L., Methylene blue as drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass. J Thorac Cardiovasc Surg 127:3 (2004 Mar), 895–896.
76. [76] Menardi, A.C., Viaro, F., Vicente, W.V., Rodrigues, A.J., Evora, P.R., Hemodynamic and vascular endothelium function studies in healthy pigs after intravenous bolus infusion of methylene blue. Arq Bras Cardiol 87:4 (2006 Oct), 525–532.
77. [77] McRobb, C.M., Holt, D.W., Methylene blue-induced methemoglobinemia during cardiopulmonary bypass? A case report and literature review. J Extra Corpor Technol 40:3 (2008 Sep), 206–214.
78. [78] Top, W.M., Gillman, P.K., de Langen, C.J., Kooy, A., Fatal methylene blue associated serotonin toxicity. Neth J Med 72:3 (2014 Apr), 179–181 PMID: 24846936.
79. [79] Clifton, J. 2nd, Leikin, J.B., Methylene blue. Am J Ther 10:4 (2003 Jul–Aug), 289–291 PMID: 12845393.
80. [80] Leite, E.G., Ronald, A., Rodrigues, A.J., Evora, P.R., Is methylene blue of benefit in treating adult patients who develop catecholamine-resistant vasoplegic syndrome during cardiac surgery?. Interact Cardiovasc Thorac Surg 5:6 (2006 Dec), 774–778.
81. [81] Roderique, J.D., VanDyck, K., Holman, B., Tang, D., Chui, B., Spiess, B.D., The use of high-dose hydroxocobalamin for vasoplegic syndrome. Ann Thorac Surg 97:5 (2014 May), 1785–1786.
82. [82] Woehlck, H.J., Boettcher, B.T., Lauer, K.K., et al. Hydroxocobalamin for vasoplegic syndrome in liver transplantation: restoration of blood pressure without vasospasm. A A Case Rep 7:12 (2016 Dec 15), 247–250.
83. [83] Boettcher, B.T., Woehlck, H.J., Reck, S.E., et al. Treatment of vasoplegic syndrome with intravenous hydroxocobalamin during liver transplantation: a report of 2 cases. J Cardiothorac Vasc Anesth, 2016 Oct 14 pii: S1053-0770(16)30500-6 10.1053/j.jvca.2016.10.011 PMID: 28012726.
84. [84] Shapiro, H., Lev, S., Cohen, J., Singer, P., Polyphenols in the prevention and treatment of sepsis syndromes: rationale and pre-clinical evidence. Nutrition 25:10 (2009 Oct), 981–997.
85. [85] Chang, S.K., Zhong, M.Z., Davis, R.F., Indigo carmine inhibits endothelium-dependent and independent vasodilation. Hypertension 27 (1996), 228–234.
86. [86] Archer, T.L., Like methylene blue, indigo carmine might counteract vasoplegia: hemodynamic evidence obtained with pulse contour analysis. J Clin Anesth 21:7 (2009 Nov), 544–546.
87. [87] Imperatore, F., Cuzzocrea, S., Luongo, C., Liguori, G., Scafuro, A., De Angelis, A., et al. Hyperbaric oxygen therapy prevents vascular derangement during zymosan induced multiple-organ-failure syndrome. Intensive Care Med 30:6 (2004 Jun), 1175–1181.
88. [88] Sun, X., Boyce, S.W., Herr, D.L., et al. Is vasoplegic syndrome more prevalent with open-heart procedures compared with isolated on-pump CABG surgery?. Cardiovasc Revasc Med 12 (2011), 203–209.